Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494798 | 0.91 | CAPN1 (0.40) | CAPN1CTSLALOX5EPHX2IDO1 | |
| SCHEMBL16495159 | 0.90 | ACHE (0.45) | CAPN1ACHEALOX5EPHX2SMYD3 | |
| SCHEMBL16495112 | 0.81 | SMYD3 (0.39) | CAPN1CTSLACHESMYD3CTSS | |
| SCHEMBL15701646 | 0.72 | ADRB2 (0.47) | CAPN1ACHEALOX5EPHX2ALDH1A1 | |
| SCHEMBL16495343 | 0.71 | ACHE (0.45) | CAPN1ACHEALOX5EPHX2 | |
| SCHEMBL16494822 | 0.71 | ACHE (0.55) | CAPN1ACHEALDH1A1 | |
| SCHEMBL697874 | 0.69 | ALOX5 (0.56) | CAPN1ACHEALOX5EPHX2 | |
| SCHEMBL700477 | 0.69 | ACHE (0.52) | CAPN1ACHEALOX5ALDH1A1 | |
| SCHEMBL7712397 | 0.69 | ACHE (0.52) | CAPN1ACHEALOX5EPHX2 | |
| SCHEMBL22088842 | 0.69 | AKT1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | CAPN1 1386/4885CTSL 609/4885ACHE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.